Sunday 18 October 2026
Export ABEO’s income statement to Excel — free account
Abeona Therapeutics Inc.
ABEO Healthcare Biotechnology
Abeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023. In the quarter to June 2026, revenue grew 225.1%, EPS fell 116.9%, free cash flow grew 17.1% and total debt fell 23.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
4.43
0.22
−4.73%
Follow ABEO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 3 | — | — | — | 2 | 3 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 4.02 |
Altman Z-Score |
4.08 | 43.26 | 1.14 | — | (4.76) | (14.08) | (16.52) | (16.67) | — | (2.32) |
P/S ratio |
192.24 | 855.63 | 113.19 | — | 11.93 | 2.48 | 5.09 | 24.06 | — | 29.73 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
1.11 | 17.95 | (3.84) | — | (11.29) | (29.98) | (35.25) | (38.47) | — | (5.75) |
Beneish M-Score |
(3.84) | (2.64) | (1.64) | — | — | — | (3.45) | 1.67 | — | — |
P/Operating CF |
(50.37) | (141.93) | (20.00) | — | (90.36) | (1.11) | (1.61) | (12.80) | — | (15.54) |
P/B ratio |
1.72 | 4.21 | 2.53 | — | 1.42 | 0.79 | 0.84 | 7.97 | — | 1.75 |
Price to Tangible BV |
2.93 | 5.36 | 5.80 | — | 2.12 | 0.82 | 0.89 | 8.80 | — | 1.77 |
EV/Sales |
118.96 | 695.84 | 86.18 | — | 4.42 | (0.60) | (5.07) | 14.52 | — | 11.47 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.09 | 0.48 | 0.00 | — | 0.00 |
EV/Operating CF |
(8.13) | (25.71) | (6.61) | — | (1.54) | 0.12 | 0.51 | (1.93) | — | (1.41) |
EV/FCF |
(7.81) | (24.77) | (5.34) | — | (1.48) | 0.12 | 0.53 | (1.92) | — | (1.28) |
Quick Ratio |
8.35 | 24.59 | 4.18 | 3.34 | 2.26 | 3.24 | 6.77 | 4.10 | 6.01 | 6.70 |
Current Ratio |
8.37 | 25.07 | 4.37 | 3.42 | 2.33 | 3.39 | 6.83 | 4.15 | 6.08 | 6.93 |
Net Debt/EBITDA |
3.00 | 5.08 | 1.52 | 1.75 | 1.21 | 0.49 | 0.97 | 1.20 | 1.29 | 2.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 3.56% | 2.30% | 11.78% | 11.88% | 0.00% | 17.41% | 9.12% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.22 | 0.29 | 0.00 | 0.43 | 0.13 |
Asset Turnover |
0.01 | 0.01 | 0.02 | 0.00 | 0.05 | 0.03 | 0.02 | 0.05 | 0.00 | 0.04 |
Operating CF/Net income |
0.60 | 0.83 | 0.69 | 0.82 | 0.42 | 0.77 | 1.00 | 0.68 | 0.88 | (1.07) |
Capex/Depreciation |
(0.63) | (1.16) | (3.92) | (0.81) | (0.24) | (0.93) | 0.35 | (0.04) | (0.84) | (2.24) |
Interest Coverage |
(3,980.17) | (3,479.50) | (5,287.82) | (192.72) | (19.79) | (24.57) | (69.18) | (112.76) | (15.26) | (23.92) |
| (26.22%) | (20.30%) | (37.27%) | (48.82%) | (59.96%) | (117.22%) | (125.79%) | (260.60%) | (216.57%) | 70.05% | |
| (22.89%) | (18.85%) | (32.09%) | (38.35%) | (44.98%) | (73.61%) | (60.47%) | (84.53%) | (73.71%) | 43.34% | |
ROIC |
(49.83%) | (53.78%) | (74.07%) | (84.35%) | (463.12%) | (6,756.62%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(35.37%) | (20.03%) | (72.71%) | (71.39%) | (125.53%) | (163.31%) | (85.15%) | (118.19%) | (71.86%) | 38.42% |
Average Days of Receivables |
50.91 | 46.66 | 9.86 | — | 0.00 | 365.00 | 48.53 | 254.87 | 0.00 | 421.13 |
Research and Development Expense of Revenue |
1,198.54% | 2,029.75% | 1,290.79% | 0.00% | 301.39% | 1,290.87% | 2,048.44% | 888.31% | 0.00% | 460.69% |
Selling, General and Administrative Expense of Revenue |
1,494.94% | 1,307.41% | 670.65% | 0.00% | 237.79% | 721.47% | 1,220.37% | 542.97% | 0.00% | 1,117.37% |
Intangible Assets out of Total Assets |
0.37 | 0.20 | 0.43 | 0.31 | 0.22 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
929.25% | 706.81% | 295.73% | 0.00% | 81.87% | 297.20% | 215.77% | 136.23% | 0.00% | 185.21% |
Graham Net Nets |
0.34 | 0.18 | 0.14 | — | 0.34 | 0.57 | 0.70 | 0.06 | — | 0.52 |
Graham Number |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 9.41 |
Earnings Yield |
(12.80%) | (3.84%) | (15.83%) | — | (57.96%) | (250.00%) | (213.97%) | (46.65%) | — | 24.86% |
Free Cash Flow Yield |
(7.92%) | (3.28%) | (14.25%) | — | (24.99%) | (208.57%) | (186.25%) | (31.41%) | — | (30.21%) |
Revenue per Share |
0.65 | 0.50 | 1.58 | 0.00 | 2.70 | 0.76 | 0.18 | 0.16 | 0.00 | 0.11 |
Operating CF per Share |
(9.52) | (13.60) | (20.57) | (31.19) | (9.45) | (16.67) | (5.53) | (1.73) | (1.36) | (1.44) |
Capex per Share |
(0.38) | (0.52) | (4.86) | (3.13) | (0.36) | (1.05) | 0.20 | (0.01) | (0.06) | (0.15) |
Free Cash Flow per Share |
(9.90) | (14.12) | (25.43) | (34.32) | (9.81) | (17.73) | (5.33) | (1.74) | (1.42) | (1.59) |
Cash per Share |
50.57 | 82.71 | 44.69 | 64.17 | 25.64 | 12.93 | 6.68 | 2.46 | 2.39 | 3.61 |
Shareholders Equity per Share |
72.48 | 102.13 | 70.51 | 88.59 | 27.67 | 10.76 | 3.40 | 0.69 | 1.07 | 3.01 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
72.48 | 102.13 | 70.51 | 88.59 | 27.67 | 10.76 | 3.40 | 0.69 | 1.07 | 3.01 |
Free Cash Flow |
(13.53) | (23.51) | (48.35) | (69.13) | (36.35) | (69.82) | (41.88) | (37.14) | (58.44) | (84.30) |
Working Capital |
61.13 | 134.99 | 68.50 | 93.69 | 55.78 | 39.67 | 45.32 | 42.32 | 84.27 | 175.34 |
Capital Expenditures |
(0.52) | (0.86) | (9.24) | (6.31) | (1.34) | (4.15) | 1.60 | (0.13) | (2.43) | (7.97) |
Net Current Asset Value |
57.46 | 131.92 | 48.50 | 87.44 | 49.10 | 19.07 | 15.65 | 6.56 | 35.95 | 144.55 |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.09 | 0.44 | 0.00 | — | 0.00 |
Capex to Sales |
0.58 | 1.03 | 3.08 | 0.00 | 0.13 | 1.38 | (1.13) | 0.04 | 0.00 | 1.37 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.14 | 0.54 | 0.25 | 0.59 | 0.49 | 0.36 | 0.80 | 0.91 | 0.66 | 0.36 |
Cash ROIC |
(8.04%) | (7.64%) | (22.08%) | (21.90%) | (18.08%) | (68.01%) | (48.21%) | (55.11%) | (36.29%) | (22.74%) |
Accounts Receivable Turnover |
7.44 | 7.25 | 31.89 | — | 0.00 | 1.95 | 0.89 | 2.66 | 0.00 | 1.39 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 1.76 | 0.00 | 0.99 | 0.15 | 0.87 | 0.00 | 0.27 |
Inventory Turnover |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 158.29 | 0.00 | 353.63 | 1,468.92 | 422.54 | 0.00 | 1,879.56 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 1,308.71 |
Average Receivables |
0.12 | 0.12 | 0.09 | — | — | 1.54 | 1.59 | 1.32 | 2.05 | 4.18 |
Average Payables |
2.28 | 2.79 | 4.00 | 4.94 | 4.23 | 4.51 | 3.07 | 1.83 | 2.65 | 5.67 |
Average Assets |
95.56 | 144.91 | 176.58 | 198.89 | 187.29 | 115.39 | 71.90 | 64.11 | 86.47 | 164.25 |
Average Common Equity |
83.41 | 134.60 | 152.07 | 156.24 | 140.49 | 72.46 | 34.56 | 20.79 | 29.43 | 101.62 |
Columns are period end dates